Inosine triphosphate pyrophosphatase 94C>A polymorphism

Clinical implications for patients with systemic lupus erythematosus treated with azathioprine

Koujirou Yamamoto, Yuko Okada, Katsunori Nakamura, Keiju Hiromura, Yoshihisa Nojima, Tomonori Nakamura

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Importance of the field: Azathioprine (AZA) has immunosuppressive property and has been widely used in organ transplantation and in several autoimmune diseases including systemic lupus erythematosus. The use of AZA is limited by the occurrence of adverse drug reactions (ADRs) leading to treatment discontinuation. Under AZA therapy, inosine triphosphate pyrophosphatase (ITPA) deficiency presumably leads to accumulation of unusual thioinosine metabolites with the potential for ADRs. Japanese patients require lower doses of AZA compared with Caucasian patients to achieve the same concentration of active metabolites. This ethnic difference in part is probably due to genetic polymorphisms of ITPA. Areas covered in this review: Relationships between ITPA genotype and enzyme activity, and efficacy and toxicity of AZA in both Caucasian and Asian populations are reviewed. Take home message: Clinical studies using a dose of <1.5 mg/kg/day in various autoimmune diseases have shown no association between ITPA genotype and ADRs. In studies using higher doses, ITPA deficiency appears to increase the risk for AZA toxicity. Genotyping of ITPA may be useful to achieve dose optimization. It is important to maintain the dose of AZA <1.5 mg/kg/day for Asian patients with ITPA 94A allele, with careful monitoring of the therapeutic efficacy.

Original languageEnglish
Pages (from-to)447-457
Number of pages11
JournalExpert Opinion on Drug Safety
Volume9
Issue number3
DOIs
Publication statusPublished - 2010 May
Externally publishedYes

Fingerprint

Pyrophosphatases
Inosine Triphosphate
Azathioprine
Systemic Lupus Erythematosus
Drug-Related Side Effects and Adverse Reactions
Autoimmune Diseases
Thioinosine
Genotype
Organ Transplantation
Genetic Polymorphisms
Immunosuppressive Agents
Therapeutics
Alleles
Enzymes

Keywords

  • Azathioprine
  • Inosine triphosphate pyrophosphatase
  • Lupus nephritis
  • Polymorphism
  • Systemic lupus erythematosus
  • Thiopurine S-methyltransferase

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Inosine triphosphate pyrophosphatase 94C>A polymorphism : Clinical implications for patients with systemic lupus erythematosus treated with azathioprine. / Yamamoto, Koujirou; Okada, Yuko; Nakamura, Katsunori; Hiromura, Keiju; Nojima, Yoshihisa; Nakamura, Tomonori.

In: Expert Opinion on Drug Safety, Vol. 9, No. 3, 05.2010, p. 447-457.

Research output: Contribution to journalArticle

Yamamoto, Koujirou ; Okada, Yuko ; Nakamura, Katsunori ; Hiromura, Keiju ; Nojima, Yoshihisa ; Nakamura, Tomonori. / Inosine triphosphate pyrophosphatase 94C>A polymorphism : Clinical implications for patients with systemic lupus erythematosus treated with azathioprine. In: Expert Opinion on Drug Safety. 2010 ; Vol. 9, No. 3. pp. 447-457.
@article{3c0d7e4790cf46c5826d5463a124b400,
title = "Inosine triphosphate pyrophosphatase 94C>A polymorphism: Clinical implications for patients with systemic lupus erythematosus treated with azathioprine",
abstract = "Importance of the field: Azathioprine (AZA) has immunosuppressive property and has been widely used in organ transplantation and in several autoimmune diseases including systemic lupus erythematosus. The use of AZA is limited by the occurrence of adverse drug reactions (ADRs) leading to treatment discontinuation. Under AZA therapy, inosine triphosphate pyrophosphatase (ITPA) deficiency presumably leads to accumulation of unusual thioinosine metabolites with the potential for ADRs. Japanese patients require lower doses of AZA compared with Caucasian patients to achieve the same concentration of active metabolites. This ethnic difference in part is probably due to genetic polymorphisms of ITPA. Areas covered in this review: Relationships between ITPA genotype and enzyme activity, and efficacy and toxicity of AZA in both Caucasian and Asian populations are reviewed. Take home message: Clinical studies using a dose of <1.5 mg/kg/day in various autoimmune diseases have shown no association between ITPA genotype and ADRs. In studies using higher doses, ITPA deficiency appears to increase the risk for AZA toxicity. Genotyping of ITPA may be useful to achieve dose optimization. It is important to maintain the dose of AZA <1.5 mg/kg/day for Asian patients with ITPA 94A allele, with careful monitoring of the therapeutic efficacy.",
keywords = "Azathioprine, Inosine triphosphate pyrophosphatase, Lupus nephritis, Polymorphism, Systemic lupus erythematosus, Thiopurine S-methyltransferase",
author = "Koujirou Yamamoto and Yuko Okada and Katsunori Nakamura and Keiju Hiromura and Yoshihisa Nojima and Tomonori Nakamura",
year = "2010",
month = "5",
doi = "10.1517/14740330903544474",
language = "English",
volume = "9",
pages = "447--457",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Inosine triphosphate pyrophosphatase 94C>A polymorphism

T2 - Clinical implications for patients with systemic lupus erythematosus treated with azathioprine

AU - Yamamoto, Koujirou

AU - Okada, Yuko

AU - Nakamura, Katsunori

AU - Hiromura, Keiju

AU - Nojima, Yoshihisa

AU - Nakamura, Tomonori

PY - 2010/5

Y1 - 2010/5

N2 - Importance of the field: Azathioprine (AZA) has immunosuppressive property and has been widely used in organ transplantation and in several autoimmune diseases including systemic lupus erythematosus. The use of AZA is limited by the occurrence of adverse drug reactions (ADRs) leading to treatment discontinuation. Under AZA therapy, inosine triphosphate pyrophosphatase (ITPA) deficiency presumably leads to accumulation of unusual thioinosine metabolites with the potential for ADRs. Japanese patients require lower doses of AZA compared with Caucasian patients to achieve the same concentration of active metabolites. This ethnic difference in part is probably due to genetic polymorphisms of ITPA. Areas covered in this review: Relationships between ITPA genotype and enzyme activity, and efficacy and toxicity of AZA in both Caucasian and Asian populations are reviewed. Take home message: Clinical studies using a dose of <1.5 mg/kg/day in various autoimmune diseases have shown no association between ITPA genotype and ADRs. In studies using higher doses, ITPA deficiency appears to increase the risk for AZA toxicity. Genotyping of ITPA may be useful to achieve dose optimization. It is important to maintain the dose of AZA <1.5 mg/kg/day for Asian patients with ITPA 94A allele, with careful monitoring of the therapeutic efficacy.

AB - Importance of the field: Azathioprine (AZA) has immunosuppressive property and has been widely used in organ transplantation and in several autoimmune diseases including systemic lupus erythematosus. The use of AZA is limited by the occurrence of adverse drug reactions (ADRs) leading to treatment discontinuation. Under AZA therapy, inosine triphosphate pyrophosphatase (ITPA) deficiency presumably leads to accumulation of unusual thioinosine metabolites with the potential for ADRs. Japanese patients require lower doses of AZA compared with Caucasian patients to achieve the same concentration of active metabolites. This ethnic difference in part is probably due to genetic polymorphisms of ITPA. Areas covered in this review: Relationships between ITPA genotype and enzyme activity, and efficacy and toxicity of AZA in both Caucasian and Asian populations are reviewed. Take home message: Clinical studies using a dose of <1.5 mg/kg/day in various autoimmune diseases have shown no association between ITPA genotype and ADRs. In studies using higher doses, ITPA deficiency appears to increase the risk for AZA toxicity. Genotyping of ITPA may be useful to achieve dose optimization. It is important to maintain the dose of AZA <1.5 mg/kg/day for Asian patients with ITPA 94A allele, with careful monitoring of the therapeutic efficacy.

KW - Azathioprine

KW - Inosine triphosphate pyrophosphatase

KW - Lupus nephritis

KW - Polymorphism

KW - Systemic lupus erythematosus

KW - Thiopurine S-methyltransferase

UR - http://www.scopus.com/inward/record.url?scp=77951636569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951636569&partnerID=8YFLogxK

U2 - 10.1517/14740330903544474

DO - 10.1517/14740330903544474

M3 - Article

VL - 9

SP - 447

EP - 457

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 3

ER -